Ionis' Akcea reports Phase I/IIa data for AKCEA-APOCIII-LRx in hypertriglyceridemia

In October, Akcea Therapeutics Inc. (NASDAQ:AKCA) reported data from a Phase I/IIa trial in about 56 healthy volunteers

Read the full 189 word article

User Sign In